I sure hope you're correct, because right now this stock is not behaving anything like being close to a "breakthrough designation" biotech stock. Quite the contrary, it's acting more like a boat anchor.
I love the enthusiasm on this board. If only a fraction of it comes to fruition, we should at least be knocking on $10 per share in the intermediate future. The problem is that I also live in reality, and $3.13 is the stark reality of the moment.
Perhaps when I'm visiting Rockefeller Center over the Christmas Break next week, I'll pay a visit to AVXL headquarters in mid-town Manhattan. I'm really curious to see what is going on over at HQ.
Market Data 
Markets 
AI
